Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
10 participants
OBSERVATIONAL
2018-12-03
2019-11-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Use of a Porcine Collagen Matrix for the Prevention of Buccal Bone Wall Resorption During Implant Placement in the Aesthetic Zone.
NCT06622759
Peri-implant Phenotype, Calprotectin and Mmp-8 Levels in Cases Diagnosed With Peri-implant Disease
NCT06173739
Clinical and Microbiological Outcomes of Dental Implants After 10-22 Years of Function
NCT06803576
Platform Switching vs Regular Platform Implants. One Year Results From a RCT
NCT02123420
Clinical and Radiographic Outcomes of Implant-supported Prostheses With Cantilever Extensions After 10 Years of Function
NCT06534398
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Clinical assessments Site-specific and full-mouth clinical indices were assessed at T0 and T1. Oral hygiene instructions using a manual toothbrush and the modified Bass technique were re-iterated at four time points over the 12-month study period (T0, 3-, 6-months and T1). Prophylaxis comprising supragingival ultrasonic debridement and polishing with a rubber cup was carried out at the same time points. In detail, the following site-specific clinical indices probing pocket depth (PPD), clinical attachment levels (CAL), recession (REC), modified gingival index (MGI) (score range 0-4) (Lobene et al. 1986), modified dental plaque index (mPI)1 (score range: 0-3) and modified sulcus bleeding index (mBI)1 (score range: 0-3) were determined at the mesial buccal site of the study implant in a similar manner as PPD, CAL, REC, MGI, plaque index (PI)2 (score range: 0-3) and sulcus bleeding index (SBI)3 (score range: 0-5) at the control tooth site. The width of keratinized tissues (KTW) was determined at the mid-buccal aspect of the test-implant/control tooth. Moreover, on a full-mouth basis PPD, CAL and dichotomous supragingival dental plaque (PI) (O'Leary et al., 1972) and bleeding on probing (BOP) (Ainamo et al., 1975) were recorded at six sites per tooth/implant present in the mouth. Periodontal clinical indices were determined using a manual periodontal probe (PCP-UNC 15; Hu-Friedy XP-23/QW, Hu-Friedy, Chicago, IL, USA) to the nearest millimeter.
Radiographic examination The VixWin™ Platinum Gendex software (Hatfield, PA, USA) linearly assessed the distance between the implant platform and the bone crest (I-BC) parallel to the long axis of the implant fixture at T0 and T1 on intra-oral digital radiographs. Periapical digital radiographs (RadioVisioGraphy; Trophy Radiology S.A., Paris, France) were obtained using the long cone paralleling technique at a 10 cm distance between the x-ray head and the digital sensor.
Collection of crevicular fluid samples Peri-implant crevicular fluid (PICF) was collected from the mesial-buccal site of the newly restored study implant, while gingival crevicular fluid (GCF) was collected from the mesial-buccal site of a contralateral control tooth at T0 and T1. Before PICF/GCF collection, the surfaces were gently air-dried and isolated from saliva by placing cotton rolls and using a saliva ejector. Then, supragingival plaque was carefully removed by sterile curettes and paper strips (Periopaper, OraFlow Inc., Smithtown, NY, USA) were gently placed in the mesial aspect of the peri-implant/gingival sulcus until mild resistance was felt and held for 30 sec. Care was taken to avoid mechanical trauma when placing the strips and those strips contaminated with blood were discarded. The strips were stored in Eppendorf tubes (Eppendorf, Hamburg, Germany) at -80C until further processed.
Proteomic analysis of crevicular fluid samples (PICF/GCF) The PICF and GCF samples collected from the study implant sites (n=10) and the control tooth sites (n=10), respectively at T0 and T1 were pooled and used for proteomics analysis. In brief, 20 µg of total protein per pooled sample were reduced, alkylated, trypsinized, and purified with single-pot, solid-phase-enhanced sample preparation (SP3) assisted protein digestion using the PreOmics' SP3-iST (PreOmics GmbH) following the manufacturing protocol for protein extraction and digestion. These extracts were concentrated using a Speedvac (Thermo Savant SPD121P, Thermo Scientific, Waltham, MA, USA) and stored at -20 °C until further use.
The digested samples were first reconstituted with 30 µL of 3% acetonitrile (ACN) in 0.1% formic acid then subjected to Fusion Orbitrap Lumos mass spectrometer (Thermo Fisher Scientific) interfaced to an Easy nano-flow HPLC system (Thermo Fisher Scientific) for proteomics analysis. During proteomics analysis, a three-liner gradient of acetonitrile and water was used with 0.1% formic acid at a 300 nL/minute flow rate. The gradient progressed from 2% to 30% acetonitrile over 60 minutes, then from 30% to 97% acetonitrile in 10 minutes, and finally held at 97% acetonitrile for 10 minutes. The mass spectrometer was set to operate in a data-dependent manner, automatically switching between MS and MS/MS using the Xcalibur software package from Thermo Fisher Scientific. A mass range of 300-1500 m/z was selected for the Orbitrap analyzer.
The acquired MS data were processed using the Mascot (version 2.4.1, Matrix Science) search engine against an in-house database containing 10,125,458 entries, which included human (accessed on 22nd February 2022 from Uniprot) and bacterial (accessed on 22nd February 2022 from eHOMD) proteins, common MS contaminants, and reverse sequences for estimating the false discovery rate. During the proteomics analysis, the precursor ion tolerance and fragment ion tolerance were set to 10 ppm and ±0.6 Da, respectively. Up to two missed cleavages per peptide were allowed for tryptic digestion. The carbamidomethylation modification on cysteine was selected as a fixed modification, while deamidation of asparagine and glutamine and oxidation of methionine were chosen as variable modification parameters.
The spectrum reports of the search results were generated using Scaffold software (version 4.2.1, Proteome software), and proteins with FDR at 1%, minimal 2 unique peptides identified, as peptide FDR at 0.1% were used for relative protein abundance analysis. Fold changes in abundance intensity were calculated based on value log2 fold change (FC) between pairs of consecutive time points using R-software (R: A Language and Environment for Statistical Computing, R Development Core Team). Proteins with a log2FC ≥ 1 of unique spectrum counts between two conditions or exclusively identified in one condition were considered regulated.
Bioinformatics analysis for the regulated proteins The regulated proteins underwent overrepresentation analysis (ORA) against the Hallmark database using the WebGestalt online tool. The analysis, conducted on March 25th, 2022, aimed to compare the regulation of proteins in teeth and implants between T0 and T1 conditions. Similarly, on March 29th, 2022, the analysis examined the regulation of proteins in both teeth and implants under either the T0 or T1 conditions. The top 10 enriched results, ranked by p-value using the hypergeometric distribution, were reported. However, only pathways with a p-value \< 0.05 were considered as regulated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Implant unit
Newly restored single implant that is closely followed for plaque control
Plaque control
Subjects are motivated for optimal oral hygiene
Tooth unit
A contralateral tooth that is closely followed for plaque control
Plaque control
Subjects are motivated for optimal oral hygiene
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plaque control
Subjects are motivated for optimal oral hygiene
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karolinska Institutet
OTHER
Aristotle University Of Thessaloniki
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Danae A. Apatzidou
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Danae A Apatzidou, Assoc. Professor
Role: STUDY_CHAIR
Dental School, Aristotle University
Danae A Apatzidou, Assoc. Professor
Role: PRINCIPAL_INVESTIGATOR
Dental School, Aristotle University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dental School, Aristotle University
Thessaloniki, , Greece
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Apatzidou DA, Violesti A, Konstantinidis A, Bao K, Silbereisen A, Bostanci N. Protein profile at newly restored implants compared to contralateral teeth over 12-months: a pilot study. Clin Oral Investig. 2024 Oct 11;28(11):590. doi: 10.1007/s00784-024-05984-w.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AUTh-29/21-11-2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.